Valuation: Beta Bionics, Inc.

Market Cap 861M 765M 709M 645M 1.22B 81.69B 1.24B 8.52B 3.34B 42.63B 3.23B 3.16B 136B P/E 2026 *
-8.1x
P/E 2027 * -7.84x
Enterprise Value 714M 635M 588M 535M 1.01B 67.76B 1.03B 7.07B 2.77B 35.36B 2.68B 2.62B 113B EV / Sales 2026 *
5.74x
EV / Sales 2027 * 4.46x
Free-Float
99.18%
Yield 2026 *
-
Yield 2027 * -
1 day-5.55%
1 week-7.26%
Current month-13.86%
1 month-23.71%
3 months-5.44%
6 months+25.96%
Current year-46.34%
1 week 16.32
Extreme 16.32
18.56
1 month 16.32
Extreme 16.32
23.56
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 14/08/2022
Director of Finance/CFO 37 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 31/01/2020
Director/Board Member 50 14/08/2022
Director/Board Member 63 30/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Sell

Executive/Senior Manager

-370 0.0007%
22/09/26 Sell

Director

-6,430 0.0143%
16/09/26 Sell

Executive/Senior Manager

-30,779 0.0684%
Change 5-day change 1-year change 3-year change Capi.($)
-5.55%-7.26%-18.33% - 861M
-0.93%+4.86%+28.03%+42.34% 255B
-1.06%+4.20%+9.56%+8.07% 161B
-0.27%+0.65%-4.36%+54.96% 151B
+0.57%+3.88%-55.27%-12.03% 64.33B
+1.47%+5.90%-13.25%-13.43% 51.9B
-0.85%+4.81%+9.39%+49.25% 50.25B
-1.70%+1.63%+16.02%+23.13% 49.92B
-1.47%+1.42%+21.88%+53.89% 48.77B
-1.62%+0.73%+30.59%+70.27% 42.93B
Average -1.14%+2.56%+2.43%+30.72% 87.58B
Weighted average by Cap. -0.70%+4.12%+8.48%+32.22%

Financials

2026 *2027 *
Net sales 124M 111M 102M 93.22M 176M 11.8B 179M 1.23B 483M 6.16B 467M 457M 19.63B 183M 162M 150M 137M 258M 17.33B 262M 1.81B 709M 9.05B 685M 671M 28.84B
Net income -93.69M -83.29M -77.19M -70.23M -133M -8.89B -135M -928M -364M -4.64B -352M -344M -14.79B -103M -91.9M -85.18M -77.5M -146M -9.81B -149M -1.02B -401M -5.12B -388M -380M -16.32B
Net Debt -147M -130M -121M -110M -208M -13.93B -211M -1.45B -570M -7.27B -551M -539M -23.17B -46.25M -41.11M -38.11M -34.67M -65.43M -4.39B -66.48M -458M -180M -2.29B -174M -170M -7.3B
Projected Income Statement - Annual - Beta Bionics, Inc.
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
16/10/26 US$16.35 -5.55% 660,849
15/10/26 US$17.31 +2.61% 1,331,132
14/10/26 US$16.87 -4.64% 892,915
13/10/26 US$17.69 -0.95% 591,352
12/10/26 US$17.86 +1.30% 820,832
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Beta Bionics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
16.35USD
Average target price
24.24USD
Spread / Average Target
+48.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Beta Bionics, Inc.
  1. Stock Market
  2. Stocks
  3. BBNX Stock